CN104968676A - 一种纯化蛋白质的方法 - Google Patents

一种纯化蛋白质的方法 Download PDF

Info

Publication number
CN104968676A
CN104968676A CN201380051960.4A CN201380051960A CN104968676A CN 104968676 A CN104968676 A CN 104968676A CN 201380051960 A CN201380051960 A CN 201380051960A CN 104968676 A CN104968676 A CN 104968676A
Authority
CN
China
Prior art keywords
haptoglobin
hemopexin
solution
resin
transferrins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380051960.4A
Other languages
English (en)
Chinese (zh)
Inventor
N·布林克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
CSL Behring LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/803,525 external-priority patent/US9534029B2/en
Application filed by CSL Behring LLC filed Critical CSL Behring LLC
Priority to CN202110206879.5A priority Critical patent/CN112717125A/zh
Publication of CN104968676A publication Critical patent/CN104968676A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380051960.4A 2012-10-03 2013-10-01 一种纯化蛋白质的方法 Pending CN104968676A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110206879.5A CN112717125A (zh) 2012-10-03 2013-10-01 一种纯化蛋白质的方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261709342P 2012-10-03 2012-10-03
US61/709,342 2012-10-03
US13/803,525 US9534029B2 (en) 2012-10-03 2013-03-14 Method of purifying proteins
US13/803,525 2013-03-14
AU2013203930 2013-04-11
AU2013203930A AU2013203930B2 (en) 2012-10-03 2013-04-11 A method of purifying proteins
EP13170202 2013-06-03
EP13170202.9 2013-06-03
PCT/US2013/062916 WO2014055552A1 (en) 2012-10-03 2013-10-01 A method of purifying proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110206879.5A Division CN112717125A (zh) 2012-10-03 2013-10-01 一种纯化蛋白质的方法

Publications (1)

Publication Number Publication Date
CN104968676A true CN104968676A (zh) 2015-10-07

Family

ID=52824845

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380051960.4A Pending CN104968676A (zh) 2012-10-03 2013-10-01 一种纯化蛋白质的方法
CN202110206879.5A Pending CN112717125A (zh) 2012-10-03 2013-10-01 一种纯化蛋白质的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110206879.5A Pending CN112717125A (zh) 2012-10-03 2013-10-01 一种纯化蛋白质的方法

Country Status (8)

Country Link
EP (1) EP2904005A1 (ja)
JP (2) JP6370792B2 (ja)
KR (2) KR102231613B1 (ja)
CN (2) CN104968676A (ja)
CA (2) CA2886726C (ja)
HK (1) HK1212995A1 (ja)
SG (1) SG11201501921SA (ja)
WO (1) WO2014055552A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111432880A (zh) * 2017-08-08 2020-07-17 瑞士杰特贝林生物制品有限公司 血色素结合蛋白制剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334441B1 (en) * 2015-08-13 2021-06-16 Kamada Ltd. Compositions derived from cohn fraction paste and use thereof
CA3019095A1 (en) * 2016-03-29 2017-10-05 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for treatment of autoimmune diseases containing antibody binding to haptoglobin in blood and forming polyvalent immune complex as an active component
JP6600123B1 (ja) * 2018-04-18 2019-10-30 積水メディカル株式会社 ヘモグロビン分析方法
CA3138650A1 (en) 2019-05-17 2020-11-26 Universitaet Zuerich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
JP2024504822A (ja) 2021-02-01 2024-02-01 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法
US20240034749A1 (en) * 2021-02-04 2024-02-01 Green Cross Corporation Method for purification of hemopexin and haptoglobin
WO2024134608A1 (en) 2022-12-22 2024-06-27 Csl Behring Ag Method of purifying hemopexin using mixed-mode chromatography

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1426039A (en) * 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
US4129648A (en) * 1977-11-21 1978-12-12 Collier Harry O J Method for reducing endogenous prostaglandin synthesis
US6093804A (en) * 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US20050153875A1 (en) * 2002-04-16 2005-07-14 Shabtai Bauer Ultrapure transferrin for pharmaceutical compositions
US20090281282A1 (en) * 2004-10-19 2009-11-12 Nhs Blood And Transplant Method for the isolation of haptoglobin

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5337406B2 (ja) * 1973-11-15 1978-10-09
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
JPS6317899A (ja) * 1986-07-09 1988-01-25 Green Cross Corp:The ハプトグロビンの精製方法
JPH01305036A (ja) * 1988-05-31 1989-12-08 Green Cross Corp:The 血漿蛋白成分の加熱処理方法および血漿蛋白成分製剤
US5169936A (en) * 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
SE9301582D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Purification of plasma proteins
DE19830914C1 (de) * 1998-07-10 1999-06-24 Centeon Pharma Gmbh Verfahren zur Herstellung einer Proteinlösung
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
DE10215315A1 (de) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
JP2004224793A (ja) * 2003-01-17 2004-08-12 Research Corp Technologies Inc 子宮内膜症の治療方法
JP2004256463A (ja) * 2003-02-26 2004-09-16 Univ Waseda 多形核白血球の細胞接着抑制剤及び細胞接着抑制方法
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
WO2007132291A2 (en) * 2006-05-15 2007-11-22 Digilab, Inc. Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes
CN101778860B (zh) * 2007-08-17 2013-07-10 Csl百灵有限公司 α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
KR101426039B1 (ko) * 2008-09-11 2014-08-01 삼성테크윈 주식회사 얼굴/물체 인식을 위한 특징점 검출 장치 및 방법
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
EP2236617A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
WO2011002070A1 (ja) * 2009-07-02 2011-01-06 協和発酵キリン株式会社 Ｇｄｆ７／ｂｍｐ１２蛋白質を含有する鉄過剰疾患または鉄濃度を低下させることが有効な疾患に対する治療用医薬組成物
ES2426098T3 (es) * 2009-07-16 2013-10-21 Institut National de la Santé et de la Recherche Médicale Composiciones farmacéuticas y su uso en el tratamiento del cáncer
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
SG178306A1 (en) * 2009-08-11 2012-03-29 Biocon Ltd Chromatographic processes and purified compounds thereof
DK2947148T3 (en) * 2010-04-20 2017-09-18 Octapharma Ag NEW STABILIZER FOR PHARMACEUTICAL PROTEINS
WO2012050874A2 (en) * 2010-09-28 2012-04-19 Soares Miguel P Targeting heme for the treatment of immune mediated inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1426039A (en) * 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
US4129648A (en) * 1977-11-21 1978-12-12 Collier Harry O J Method for reducing endogenous prostaglandin synthesis
US6093804A (en) * 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US20050153875A1 (en) * 2002-04-16 2005-07-14 Shabtai Bauer Ultrapure transferrin for pharmaceutical compositions
US20090281282A1 (en) * 2004-10-19 2009-11-12 Nhs Blood And Transplant Method for the isolation of haptoglobin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARCIA R. MAUK等: "Metal Ion Binding to Human Hemopexin", 《BIOCHEMISTRY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111432880A (zh) * 2017-08-08 2020-07-17 瑞士杰特贝林生物制品有限公司 血色素结合蛋白制剂

Also Published As

Publication number Publication date
JP6370792B2 (ja) 2018-08-08
KR20150063547A (ko) 2015-06-09
KR20200075027A (ko) 2020-06-25
KR102125695B1 (ko) 2020-06-24
JP2015532301A (ja) 2015-11-09
WO2014055552A1 (en) 2014-04-10
CN112717125A (zh) 2021-04-30
JP2018172426A (ja) 2018-11-08
EP2904005A1 (en) 2015-08-12
JP6876655B2 (ja) 2021-05-26
CA3129057A1 (en) 2014-04-10
HK1212995A1 (zh) 2016-06-24
SG11201501921SA (en) 2015-04-29
KR102231613B1 (ko) 2021-03-25
CA2886726C (en) 2021-11-23
CA2886726A1 (en) 2014-04-10
CA3129057C (en) 2023-03-07

Similar Documents

Publication Publication Date Title
US10918696B2 (en) Methods of treatment using hemopexin compositions
CN104968676A (zh) 一种纯化蛋白质的方法
ES2229784T3 (es) Proceso de produccion de inmunoglobulinas para administracion intravenosa y otros productos de inmunoglobulina.
US6806355B2 (en) Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
JPH09509165A (ja) ミルクからのラクトフェリンの分離
EA022821B1 (ru) Способ получения биологически активного рекомбинантного г-ксф человека
JPH06107561A (ja) 静脈内相容性免疫グロブリン− ｇ− 製剤の製造方法
US9145448B2 (en) Method for the isolation of haptoglobin
RU2157240C2 (ru) Способ получения иммуноглобулинов из фракций, которые образуются при фракционировании человеческой плазмы крови
AU2002321012B2 (en) A purification process for large scale production of Gc-globulin, product obtained thereby and their use in medicine
WO2024134608A1 (en) Method of purifying hemopexin using mixed-mode chromatography
Grellet et al. An associated process for the purification of immuno globulin g, catalase, superoxide dismutase and albumin from haemolysed human placenta blood
WO2024187231A1 (en) Single step process for preparation of pure immunoglobulin from plasma
JPH01165393A (ja) 組換えヒトエリスロポエチンの精製方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151102

Address after: Bern

Applicant after: Csl Behring AG

Address before: American Pennsylvania

Applicant before: CSL BEHRING LLC

RJ01 Rejection of invention patent application after publication

Application publication date: 20151007

RJ01 Rejection of invention patent application after publication